China GMP
Form: DPI
Strength: 18mcg
Indication: indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is indicated to reduce exacerbations in COPD patients
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>This category refers to <strong>long-acting muscarinic antagonist (LAMA) powder formulations</strong> designed for inhalation therapy. Manufactured under strict pharmaceutical GMP standards, the active ingredient is a dry powder blend optimized for pulmonary delivery systems.</p>
<h3>Application</h3>
<ul>
<li><strong>Clinical Settings:</strong> Chronic obstructive pulmonary disease (COPD) management in hospitals and clinics.</li>
<li><strong>Distribution:</strong> Wholesale supply to pharmacies and respiratory care centers.</li>
<li><strong>R&D:</strong> Raw material sourcing for generic drug manufacturers developing bronchodilator solutions.</li>
</ul>
<h3>Precautions</h3>
<ul>
<li><strong>Safety:</strong> Requires controlled environment storage to prevent moisture absorption and ensure particle integrity.</li>
<li><strong>Maintenance:</strong> Inhalation devices must undergo periodic cleaning and calibration to maintain dosage accuracy.</li>
</ul>